

Pharmacology of Antiarrhythmics and Antihypertensives

Sara H. Shields
Rachel M. Holland
R. Dustin Pippin
Benjamin Small

REFERENCES

1. Sampson KJ, Kass RS: Chapter 29. Anti-arrhythmic drugs, in Brunton LL, Chabner BA, Knollmann BC (eds): *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 12th ed. New York: McGraw-Hill; 2011.
2. Nattel S, Andrade J, Macle L, et al: New directions in cardiac arrhythmia management: present challenges and future solutions. *Can J Cardiol* 30: S420, 2014. [PMID: 25432137]
3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N Engl J Med* 321: 406, 1989. [PMID: 2473403]
4. Waldo AL, Camm AJ, deRuyter H, et al: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral sotalol. *Lancet* 348: 7, 1996. [PMID: 8691967]
5. Connolly SJ, Camm AJ, Halperin JL, et al: Dronedronarone in high-risk permanent atrial fibrillation. *N Engl J Med* 365: 2268, 2011. [PMID: 22082198]
6. Drug Monograph, Access Emergency Medicine, McGraw-Hill. <http://accessemergency-medicine.mhmedical.com/drugs.aspx>. Accessed December 12, 2014.
7. Neumar RW, Otto CW, Link MS, et al: Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 122: S729, 2010.
8. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N Engl J Med* 121: 406, 1989. [PMID: 2473403]
9. Myerburg RJ, Mitrani R, Interian A Jr: Interpretation of outcomes of antiarrhythmic clinical trials. Design features and population impact. *Circulation* 97: 1514, 1998.
10. January CT, Wann LS, Alpert JS, et al: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 64: e1, 2014. [PMID: 24682348]
11. Desai AD, Chun S, Sung RJ: The role of intravenous amiodarone in the management of cardiac arrhythmias. *Ann Intern Med* 127: 294, 1997. [PMID: 9265430]
12. Product Information: Cordarone(R) IV, amiodarone. Philadelphia, PA: Wyeth Laboratories; 2002.
13. Nexterone Amiodarone IV (R) [package insert]. Deerfield, IL: Baxter Healthcare Corporation; 1985.
14. Dorian P, Cass D, Schwartz B, et al: Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. *N Engl J Med* 346: 884, 2002. [PMID: 11907287]
15. Kudenchuk PJ, Cobb LA, Copass MK, et al: Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. *N Engl J Med* 341: 871, 1999. [PMID: 10486418]
16. Haldal M, Atar D: Pharmacologic conversion of recent-onset atrial fibrillation: a systematic review. *Scand Cardiovasc J* 47: 2, 2013. [PMID: 23067130]
17. Trissel LA. *Handbook on Injectable Drugs*. Bethesda, MD: American Society of Health-System Pharmacists; 2005.
18. Goldschlager N, Epstein AE, Naccarelli GV, et al: Practical guide for clinicians who treat patients with amiodarone. *Heart Rhythm* 4: 1250, 2007. [PMID: 17765636]
19. Multaq® [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S., LLC; 2009.
20. Sotalol® [package insert]. Weston, FL: Apotex Corp.; 2004.
21. Product Information: Tikosyn (Dofetilide). New York: Pfizer, Inc.; 2011.
22. Brinavess® [package insert]. London: Cardiome UK Limited; 2012.
23. Holdgate A, Foo A: Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adults. *Cochrane Database Syst Rev* 4: CD005154, 2006. [PMID: 17054240]
24. Reynolds MR: Outcomes with digoxin in atrial fibrillation: more data, no answers. *J Am Coll Cardiol* 64: 669, 2014. [PMID: 25125297]
25. Friberg L, Hammar N, Rosenqvist M: Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). *Heart* 96: 275, 2010. [PMID: 19710030]
26. Gheorghiadu M, Fonarow GC, van Veldhuisen DJ, et al: Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. *Eur Heart J* 34: 1489, 2013. [PMID: 23592708]
27. Turakhia MP, Santangeli P, Winkelmayer WC, et al: Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. *J Am Coll Cardiol* 64: 660, 2014. [PMID: 25125296]
28. Shah M, Avgil Tsadok M, Jackevicius CA, et al: Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. *Am J Cardiol* 114: 401, 2014. [PMID: 24950677]
29. Herroeder S, Scho ME, De Hert SG, Hollmann MW: Magnesium—essentials for anesthesiologists. *Anesthesiology* 114: 971, 2011. [PMID: 21364460]